,title,source,link,date
61,Determining Who Should Get Quadruplet Vs Triplet Therapy in ...,Cancer Network,news.google.com/articles/CBMib2h0dHBzOi8vd3d3LmNhbmNlcm5ldHdvcmsuY29tL3ZpZXcvZGV0ZXJtaW5pbmctd2hvLXNob3VsZC1nZXQtcXVhZHJ1cGxldC12cy10cmlwbGV0LXRoZXJhcHktaW4tbXVsdGlwbGUtbXllbG9tYdIBAA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-08-26
53,Ivonescimab Challenges Tislelizumab Plus Chemo in Advanced ...,Targeted Oncology,news.google.com/articles/CBMiaWh0dHBzOi8vd3d3LnRhcmdldGVkb25jLmNvbS92aWV3L2l2b25lc2NpbWFiLWNoYWxsZW5nZXMtdGlzbGVsaXp1bWFiLXBsdXMtY2hlbW8taW4tYWR2YW5jZWQtZWdmci1ucy1uc2NsY9IBAA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-08-26
12,Up-to-date meta-analysis of long-term evaluations of mesenchymal ...,Newswise,news.google.com/articles/CBMikQFodHRwczovL3d3dy5uZXdzd2lzZS5jb20vYXJ0aWNsZXMvdXAtdG8tZGF0ZS1tZXRhLWFuYWx5c2lzLW9mLWxvbmctdGVybS1ldmFsdWF0aW9ucy1vZi1tZXNlbmNoeW1hbC1zdGVtLWNlbGwtdGhlcmFweS1mb3ItY29tcGxleC1wZXJpYW5hbC1maXN0dWxh0gEA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-08-26
37,Charina Toste Discusses the Educational Obstacles Patients With ...,www.oncnursingnews.com/,news.google.com/articles/CBMibWh0dHBzOi8vd3d3Lm9uY251cnNpbmduZXdzLmNvbS92aWV3L2NoYXJpbmEtdG9zdGUtZGlzY3Vzc2VzLXRoZS1lZHVjYXRpb25hbC1vYnN0YWNsZXMtcGF0aWVudHMtd2l0aC1tcG5zLWZhY2XSAQA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-08-25
49,Dr Williams on the Mechanism of Action of ADCs in Ovarian Cancer,OncLive,news.google.com/articles/CBMiXWh0dHBzOi8vd3d3Lm9uY2xpdmUuY29tL3ZpZXcvZHItd2lsbGlhbXMtb24tdGhlLW1lY2hhbmlzbS1vZi1hY3Rpb24tb2YtYWRjcy1pbi1vdmFyaWFuLWNhbmNlctIBAA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-08-25
73,FDA Approves First Biosimilar of Natalizumab for the Treatment of ...,Pharmacy Times,news.google.com/articles/CBMigQFodHRwczovL3d3dy5waGFybWFjeXRpbWVzLmNvbS92aWV3L2ZkYS1hcHByb3Zlcy1maXJzdC1iaW9zaW1pbGFyLW9mLW5hdGFsaXp1bWFiLWZvci10aGUtdHJlYXRtZW50LW9mLXJlbGFwc2luZy1tdWx0aXBsZS1zY2xlcm9zaXPSAQA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-08-25
44,FDA Accepts sBLA for Amivantamab/Chemo in EGFR Exon 20+ ...,Cancer Network,news.google.com/articles/CBMiX2h0dHBzOi8vd3d3LmNhbmNlcm5ldHdvcmsuY29tL3ZpZXcvZmRhLWFjY2VwdHMtc2JsYS1mb3ItYW1pdmFudGFtYWItY2hlbW8taW4tZWdmci1leG9uLTIwLW5zY2xj0gEA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-08-25
41,LEAP-010 Trial Discontinued After OS Projection With ...,OncLive,news.google.com/articles/CBMifmh0dHBzOi8vd3d3Lm9uY2xpdmUuY29tL3ZpZXcvbGVhcC0wMTAtdHJpYWwtZGlzY29udGludWVkLWFmdGVyLW9zLXByb2plY3Rpb24td2l0aC1wZW1icm9saXp1bWFiLWxlbnZhdGluaWItaW4tbWV0YXN0YXRpYy1obnNjY9IBAA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-08-25
38,FDA Clears Investigational New Drug Application to Treat ...,Pharmacy Times,news.google.com/articles/CBMieWh0dHBzOi8vd3d3LnBoYXJtYWN5dGltZXMuY29tL3ZpZXcvZmRhLWNsZWFycy1pbnZlc3RpZ2F0aW9uYWwtbmV3LWRydWctYXBwbGljYXRpb24tdG8tdHJlYXQtYW15b3Ryb3BoaWMtbGF0ZXJhbC1zY2xlcm9zaXPSAQA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-08-25
33,ASCO Reading Room | Immunotherapy for ROS1-Rearranged ...,Medpage Today,news.google.com/articles/CBMiNGh0dHBzOi8vd3d3Lm1lZHBhZ2V0b2RheS5jb20vYXNjby9sdW5nLWNhbmNlci8xMDYwNDDSAQA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-08-25
